Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 MesoblastInhibrxAdverum BiotechnologiesCortexymeCoherus BioSciences
SymbolNASDAQ:MESONASDAQ:INBXNASDAQ:ADVMNASDAQ:CRTXNASDAQ:CHRS
Price Information
Current Price$8.51$20.33$9.56$38.40$14.63
52 Week RangeHoldBuyBuyHoldBuy
MarketRank™
Overall Score1.41.61.51.31.4
Analysis Score3.23.53.43.13.4
Community Score3.12.92.42.62.5
Dividend Score0.00.00.00.00.0
Ownership Score0.00.81.70.80.0
Earnings & Valuation Score0.60.60.00.01.3
Analyst Ratings
Consensus RecommendationHoldBuyBuyHoldBuy
Consensus Price Target$14.55$34.67$23.50$50.00$26.60
% Upside from Price Target70.98% upside70.52% upside145.82% upside30.21% upside81.82% upside
Trade Information
Market Cap$1.10 billion$767.42 million$936.18 million$1.13 billion$1.07 billion
Beta3.71N/A1.720.951.57
Average Volume555,158143,258830,542302,6001,307,086
Sales & Book Value
Annual Revenue$32.16 millionN/A$250,000.00N/A$356.07 million
Price / Sales34.33N/A3,744.73N/A3.00
CashflowN/AN/AN/AN/A$1.10 per share
Price / CashN/AN/AN/AN/A13.36
Book Value$4.70 per shareN/A$2.71 per share$4.30 per share$1.50 per share
Price / Book1.81N/A3.53N/A9.75
Profitability
Net Income$-77,940,000.00N/A$-64,490,000.00$-36,980,000.00$89.83 million
EPS($0.74)N/A($1.01)($1.94)$1.23
Trailing P/E RatioN/A0.00N/AN/A7.17
Forward P/E RatioN/AN/AN/AN/A16.63
P/E GrowthN/AN/AN/AN/A9.34
Net Margins-591.00%N/AN/AN/A33.06%
Return on Equity (ROE)-18.69%N/A-32.23%-37.78%90.98%
Return on Assets (ROA)-13.85%N/A-28.02%-35.24%27.33%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.10%0.18%N/AN/A1.58%
Current Ratio1.32%3.80%28.53%8.71%5.45%
Quick Ratio1.32%3.80%28.53%8.71%5.18%
Ownership Information
Institutional Ownership Percentage2.80%36.63%97.41%55.48%N/A
Insider Ownership Percentage18.80%N/A12.40%19.80%15.86%
Miscellaneous
Employees1028416737317
Shares Outstanding129.74 million37.75 million97.93 million29.55 million73.11 million
Next Earnings Date5/26/2021 (Estimated)6/11/2021 (Estimated)5/27/2021 (Estimated)5/11/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Coherus BioSciences (NASDAQ:CHRS) Trading Up 2.8%Coherus BioSciences (NASDAQ:CHRS) Trading Up 2.8%
americanbankingnews.com - April 20 at 1:58 PM
Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi BiosciencesCoherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences
finance.yahoo.com - April 20 at 11:00 AM
 Analysts Anticipate Coherus BioSciences, Inc. (NASDAQ:CHRS) to Post $0.09 Earnings Per Share Analysts Anticipate Coherus BioSciences, Inc. (NASDAQ:CHRS) to Post $0.09 Earnings Per Share
americanbankingnews.com - April 18 at 10:16 AM
Coherus BioSciences (NASDAQ:CHRS) vs. Taysha Gene Therapies (NASDAQ:TSHA) Head-To-Head ContrastCoherus BioSciences (NASDAQ:CHRS) vs. Taysha Gene Therapies (NASDAQ:TSHA) Head-To-Head Contrast
americanbankingnews.com - April 14 at 3:20 PM
The Market Doesnt Like What It Sees From Coherus BioSciences, Inc.s (NASDAQ:CHRS) Earnings YetThe Market Doesn't Like What It Sees From Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Earnings Yet
nasdaq.com - April 13 at 9:23 AM
Coherus BioSciences Sees Unusually Large Options Volume (NASDAQ:CHRS)Coherus BioSciences Sees Unusually Large Options Volume (NASDAQ:CHRS)
americanbankingnews.com - April 13 at 7:18 AM
Coherus BioSciences (NASDAQ:CHRS) Reaches New 12-Month Low at $13.70Coherus BioSciences (NASDAQ:CHRS) Reaches New 12-Month Low at $13.70
americanbankingnews.com - April 12 at 11:08 AM
Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Buy" by BrokeragesCoherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 10 at 9:08 AM
Head to Head Comparison: Forma Therapeutics (NASDAQ:FMTX) vs. Coherus BioSciences (NASDAQ:CHRS)Head to Head Comparison: Forma Therapeutics (NASDAQ:FMTX) vs. Coherus BioSciences (NASDAQ:CHRS)
americanbankingnews.com - April 8 at 12:26 AM
Coherus BioSciences (NASDAQ:CHRS) Stock Price Up 3.7%Coherus BioSciences (NASDAQ:CHRS) Stock Price Up 3.7%
americanbankingnews.com - April 7 at 12:30 PM
Coherus BioSciences (NASDAQ:CHRS) Hits New 52-Week Low at $14.00Coherus BioSciences (NASDAQ:CHRS) Hits New 52-Week Low at $14.00
americanbankingnews.com - April 5 at 1:28 PM
Coherus BioSciences (NASDAQ:CHRS) Stock Rating Upgraded by Zacks Investment ResearchCoherus BioSciences (NASDAQ:CHRS) Stock Rating Upgraded by Zacks Investment Research
marketbeat.com - April 2 at 7:13 PM
 Brokerages Anticipate Coherus BioSciences, Inc. (NASDAQ:CHRS) to Announce $0.09 Earnings Per Share Brokerages Anticipate Coherus BioSciences, Inc. (NASDAQ:CHRS) to Announce $0.09 Earnings Per Share
americanbankingnews.com - March 31 at 6:28 PM
Coherus BioSciences (NASDAQ:CHRS) Reaches New 12-Month Low at $14.02Coherus BioSciences (NASDAQ:CHRS) Reaches New 12-Month Low at $14.02
americanbankingnews.com - March 30 at 12:42 PM
I Ran A Stock Scan For Earnings Growth And Coherus BioSciences (NASDAQ:CHRS) Passed With EaseI Ran A Stock Scan For Earnings Growth And Coherus BioSciences (NASDAQ:CHRS) Passed With Ease
finance.yahoo.com - March 23 at 7:27 AM
Coherus announces start of rolling submission of Toripalimab marketing applicationCoherus announces start of rolling submission of Toripalimab marketing application
seekingalpha.com - March 5 at 8:01 AM
Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for ...Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for ...
apnews.com - March 3 at 9:31 AM
Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal CarcinomaJunshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
finance.yahoo.com - March 3 at 9:30 AM
Coherus Management to Present at Upcoming Investor ConferencesCoherus Management to Present at Upcoming Investor Conferences
finance.yahoo.com - February 25 at 1:13 PM
Coherus BioSciences Inc (CHRS) Q4 2020 Earnings Call TranscriptCoherus BioSciences Inc (CHRS) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 25 at 1:46 AM
Coherus BioSciences (CHRS) Misses Q4 Earnings and Revenue EstimatesCoherus BioSciences (CHRS) Misses Q4 Earnings and Revenue Estimates
nasdaq.com - February 24 at 8:45 PM
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial ResultsCoherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - February 24 at 8:45 PM
Earnings Preview: Coherus BioSciences (CHRS) Q4 Earnings Expected to DeclineEarnings Preview: Coherus BioSciences (CHRS) Q4 Earnings Expected to Decline
nasdaq.com - February 19 at 9:23 AM
Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24thCoherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th
finance.yahoo.com - February 18 at 8:39 AM
Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for ReviewCoherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
markets.businessinsider.com - February 17 at 9:08 AM
Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for ReviewCoherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
finance.yahoo.com - February 17 at 9:08 AM
DateCompanyBrokerageAction
4/13/2021MesoblastMaxim GroupUpgrade
1/19/2021MesoblastJefferies Financial GroupDowngrade
12/15/2020MesoblastHC WainwrightReiterated Rating
12/4/2020MesoblastChardan CapitalDowngrade
10/22/2020MesoblastRoyal Bank of CanadaInitiated Coverage
5/28/2020MesoblastLADENBURG THALM/SH SHBoost Price Target
12/19/2019MesoblastDawson JamesInitiated Coverage
10/22/2019MesoblastCantor FitzgeraldReiterated Rating
9/10/2019MesoblastOppenheimerSet Price Target
2/3/2021InhibrxCredit Suisse GroupBoost Price Target
10/15/2020InhibrxLifesci CapitalReiterated Rating
9/14/2020InhibrxEvercore ISIInitiated Coverage
12/15/2020Adverum BiotechnologiesUBS GroupInitiated Coverage
11/12/2020Adverum BiotechnologiesRaymond JamesUpgrade
8/11/2020Adverum BiotechnologiesSVB LeerinkBoost Price Target
8/10/2020Adverum BiotechnologiesPiper SandlerBoost Price Target
5/5/2020Adverum BiotechnologiesSunTrust BanksUpgrade
4/28/2020Adverum BiotechnologiesThe Goldman Sachs GroupInitiated Coverage
1/13/2020Adverum BiotechnologiesPiper Jaffray CompaniesBoost Price Target
12/11/2020CortexymeSmith Barney CitigroupInitiated Coverage
12/11/2020CortexymeCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
12/7/2020CortexymeBank of AmericaUpgrade
5/13/2020CortexymeCanaccord GenuityReiterated Rating
6/3/2019CortexymeJMP SecuritiesInitiated Coverage
11/19/2020Coherus BioSciencesMizuhoLower Price Target
2/6/2020Coherus BioSciencesJPMorgan Chase & Co.Boost Price Target
8/12/2019Coherus BioSciencesBarclaysSet Price Target
(Data available from 4/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.